EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieRandomisierte kontrollierte Studie

Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial

Yiwen Ling, Li Xuan, Na Xu, Fen Huang iD, Zhiping Fan, Ziwen Guo, Xiaojun Xu, Hui Liu, Ren Lin, Sijian Yu, Haiyan Zhang, Hua Jin und 11 weitere

Journal of Clinical Oncology · 2023

DOI: 10.1200/jco.23.00101 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2023. Verfasst von Yiwen Ling und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE The busulfan plus fludarabine (BuFlu) conditioning regimen has lower transplant-related mortality (TRM) than busulfan plus cyclophosphamide (BuCy) in HLA-matched transplantation. We aimed to compare outcomes of the BuFlu regimen with those of the BuCy regimen in HLA-haploidentical hematopoietic cell transplantation (haplo-HCT). METHODS We performed an open-label, randomized phase III trial at 12 hospitals in China. Eligible patients with AML (18-65 years) were randomly assigned 1:1 to receive BuFlu (busulfan 0.8 mg/kg four times per day on days –6 to –3; fludarabine 30 mg/m 2 once daily on days –7 to –3) or BuCy (same dose of busulfan; cyclophosphamide 60 mg/kg once daily on days –3 and –2). The primary end point was 1-year TRM in the intention-to-treat population and safety in the per-protocol population. This trial is registered with ClinicalTrials.gov (identifier: NCT02487069 ) and is complete. RESULTS From November 20, 2015, to September 30, 2019, 386 patients were randomly assigned to receive the BuFlu (n = 194) or BuCy (n = 192) regimen. The median follow-up was 55.0 (IQR, 46.5-69.0) months after random assignment. The 1-year TRM was 7.2% (95% CI, 4.1 to 11.4) and 14.1% (95% CI, 9.6 to 19.4; hazard ratio [HR], 0.51; 95% CI, 0.27 to 0.97; P = .041), the 5-year relapse was 17.9% (95% CI, 9.6 to 28.3) and 14.2% (95% CI, 9.1 to 20.5; HR, 1.12; 95% CI, 0.65 to 1.95; P = .670), and the 5-year overall survival was 72.5% (95% CI, 62.2 to 80.4) and 68.2% (95% CI, 58.9 to 75.9; HR, 0.84; 95% CI, 0.56 to 1.26; P = .465) in two groups, respectively. Grade 3 regimen-related toxicity (RRT) was reported for 0 of 191 patients following the BuFlu regimen and 9 (4.7%) of 190 patients following the BuCy regimen ( P = .002). At least one type of grade 3-5 adverse event was reported for 130 (68.1%) of the 191 patients and 147 (77.4%) of the 190 patients in two groups, respectively ( P = .041). CONCLUSION The BuFlu regimen has a lower TRM and RRT and similar relapse for patients with AML undergoing haplo-HCT compared with the BuCy regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteHumansBusulfanCyclophosphamideRecurrenceTransplantation ConditioningVidarabineDrug Therapy, CombinationAdolescentYoung AdultAdultMiddle AgedAged

Substanzen

BusulfanCyclophosphamidefludarabineVidarabine

Autor:innen und Institutionen

  • Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Clinical Medical Research Center of Hematological Diseases of Guangdong Province, Guangzhou, China.
  • Department of Hematology, the First People Hospital of Foshan, Foshan, China.
  • Department of Hematology, Zhongshan City People's Hospital, Zhongshan, China.
  • Department of Hematology, the Seven Affiliated Hospital of Sun Yat-Sen University, Shenzhen, China.
  • Department of Hematology, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.

ORCID-Profile: Fen Huang, Qifa Liu

Zitieren

APA

Ling, Y., Xuan, L., Xu, N., Huang, F., Fan, Z., Guo, Z., Xu, X., Liu, H., Lin, R., Yu, S., Zhang, H., Jin, H., Wu, M., Liu, C., Liang, X., Ou, R., Zhang, Y., Liu, X., Qu, H., …, & Liu, Q. (2023). Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.00101

Vancouver

Ling Y, Xuan L, Xu N, Huang F, Fan Z, Guo Z, et al. Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial. Journal of Clinical Oncology. 2023. doi:10.1200/jco.23.00101

BibTeX
@article{Ling2023,
  author = {Ling, Yiwen and Xuan, Li and Xu, Na and Huang, Fen and Fan, Zhiping and Guo, Ziwen and Xu, Xiaojun and Liu, Hui and Lin, Ren and Yu, Sijian and Zhang, Haiyan and Jin, Hua and Wu, Meiqing and Liu, Can and Liang, Xinquan and Ou, Ruiming and Zhang, Yuping and Liu, Xiaodan and Qu, Hong and Zhai, Xiao and Sun, Jing and Zhao, Ying and Liu, Qifa},
  title = {Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation: A Multicenter Randomized Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  doi = {10.1200/jco.23.00101}
}
Kostenlos starten →